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Abstract
Asphyxiated newborns may be hemodynamically unstable during their first days of 
life. They often present with severe persistent pulmonary hypertension and/or car-
diac dysfunction, which may require aggressive supportive management to maintain 
homeostasis and prevent further brain injury. In the most severe cases, extracorporeal 
membrane oxygenation (ECMO) may be required to ensure adequate oxygenation, 
ventilation and cardiac output. However, due to the risk of irreversible brain injury, 
clinicians often are concerned about offering ECMO to these newborns. Therapeutic 
hypothermia during the first days of life has become the standard of care for these 
newborns to improve their prognosis; however, this treatment in itself has been associ-
ated with increased hemodynamic instability and coagulopathy. An additional con-
cern with using ECMO in these newborns is the potential increased bleeding risk when 
continuing the hypothermia treatment during the ECMO course. This chapter reviews 
the reported feasibility of performing hypothermia during ECMO. We also review the 
reported outcomes of asphyxiated newborns treated with hypothermia and ECMO 
and highlight their potential survival without neurodevelopmental impairments. 
Thus, ECMO should be considered as a therapeutic option for asphyxiated newborns 
treated with hypothermia.
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1. Introduction
Neonatal encephalopathy secondary to perinatal asphyxia is a common condition, with a 
global incidence varying between 1.3 and 6.6‰ depending on birth location [1]. It is associ-
ated with significant mortality (i.e., 23% of all neonatal deaths worldwide) and long-term 
morbidity, including cerebral palsy and global developmental delay [2–4]. In developed 
countries, therapeutic hypothermia has become the standard treatment for newborns born 
at 36 or more weeks of gestational age who have suffered from birth asphyxia and who 
present with moderate to severe encephalopathy in the first hours of life [5]. Hypothermia 
treatment has been shown to reduce the risk of death and long-term disability in these 
newborns [6, 7].
Hemodynamic instability can develop after birth asphyxia and during hypothermia [8], 
and may be so severe that some of these asphyxiated newborns treated with hypother-
mia require support with extracorporeal membrane oxygenation (ECMO) [9–11]. First, 
transient myocardial ischemia and papillary muscle dysfunction due to subendocardial 
ischemia occur in one-third of asphyxiated newborns [12, 13]. Second, pulmonary vascular 
resistances in these newborns are high due to hypoxia-induced pulmonary vasoconstric-
tion, and thus pulmonary hypertension frequently co-exists along with the cardiac dys-
function. Acute pulmonary hypertension may lead to a reduction in the right ventricular 
function, which, if left untreated, subsequently can impair the left ventricular filling, and 
hence explain a lower cardiac output [14]. In addition, therapeutic hypothermia results in 
a lower heart rate in these newborns and a reduction of cardiac output, which reflect the 
adaptation to the decreased tissue demand during hypothermia treatment [15]. Evidence 
is accumulating that this hemodynamic instability (including hypotension and persistent 
pulmonary hypertension) and associated metabolic acidosis and hypoxemia have the 
potential to worsen brain injury in these newborns [16–18], and thus deserve early and 
optimal management. Therefore, optimizing the hemodynamic profile of these newborns 
as early as possible is of the utmost importance for decreasing their risk of further brain 
injury, even if this requires initiation of ECMO.
2. General aspects of neonatal ECMO
The first reported successful use of neonatal ECMO was in 1975 with a newborn who had 
meconium aspiration syndrome [19]. Since then, the neonatal ECMO field has evolved rap-
idly along with the indications and contraindications for this therapy. Broadly, ECMO usu-
ally is indicated in newborns for disease processes—believed to be reversible—associated 
with high mortality.
One of the largest randomized clinical trials of ECMO with newborns was undertaken by 
the United Kingdom collaborative ECMO trial group [20]. This study enrolled a total of 
185 newborns with gestational age ≥35 weeks and birth weight ≥2 kg. The main indication 
for ECMO in this study was severe respiratory failure with an oxygenation index ≥40. The 
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primary diagnosis was persistent pulmonary hypertension, meconium aspiration, congenital 
diaphragmatic hernia, sepsis, and idiopathic respiratory distress. The results suggested sig-
nificant survival benefits for the newborns, who received ECMO, with a relative risk reduc-
tion of 0.55 (95% CI 0.39–0.77) (p = 0.0005). These results translate into four newborns, who 
needed to be treated with ECMO for one newborn to benefit from a reduction in mortality.
As of mid-2017, the international extracorporeal life support organization (ELSO) registry 
reported a total of 35,598 neonatal runs of ECMO worldwide in active centers [21]. The major-
ity of these neonatal ECMO runs were for pulmonary indications (75%) and a smaller pro-
portion for cardiac indications (20%); extracorporeal cardiopulmonary resuscitation (ECPR) 
constituted only 5% of the total neonatal ECMO runs [21].
Several studies have reported on the short- and long-term outcomes of newborns treated 
with ECMO (22, 23). Some of these studies have found that newborns treated with ECMO 
are at an increased risk of death and neurodevelopmental impairments [22, 23]. However, 
a population-based study, which reported the outcomes of 224 newborns treated with 
ECMO for various indications between 1993 and 2000, showed that 86% of these new-
borns survived, and 49% had a normal development in the motor, cognitive, and behav-
ioral domains at 5 years of age. The survival and long-term outcomes of newborns, who 
received ECMO, have been shown to depend significantly on the underlying disease and 
the indication for ECMO [24, 25]. For example, newborns with congenital diaphragmatic 
hernia had lower survival rates and a higher incidence of long-term neurodevelopmental 
impairments, compared to newborns treated with ECMO for other indications, such as 
meconium aspiration syndrome [25].
ECMO-related brain injury is a multifactorial process in which factors related to the pre- 
ECMO illness and events during the ECMO course (including cannulation) play a role [26–30]. 
During cannulation, a period occurs of decreased blood flow and potential hypoxia when the 
neck vessels need to be ligated. In veno-arterial (VA) ECMO, the lack of pulsatile blood flow 
may lead to endothelial dysfunction, which could contribute to the lack of brain autoregu-
lation [29, 30]. In veno-venous (VV) ECMO, even if the carotid artery is spared, a concern 
exists about venous congestion due to the obstructive nature of the cannula, which can lead to 
systemic venous congestion and a higher incidence of posterior fossa hemorrhage, compared 
to patients who are treated with VA ECMO [27, 28]. Thus, although neonatal ECMO has sig-
nificantly improved the prognosis of some critically ill newborns, it still is associated with a 
non-negligible risk for brain injury in the treated newborns.
3. ECMO and therapeutic hypothermia
Clinicians raise concern about increased bleeding risk when providing therapeutic hypo-
thermia during ECMO support. However, several studies have reported the short- and 
long-term outcomes of newborns treated with ECMO and hypothermia without bleeding 
complications. Hichiba et al. [31] found that newborns with a body weight between 2 and 5 
kg, who were treated with ECMO for severe respiratory failure, could receive hypothermia 
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treatment down to 34°C for 12 h while on ECMO without worsening their survival rate, 
hemodynamic instability, bleeding risk, and thromboembolic complications. Horan et al. 
[32] found that newborns who were more than 33 weeks of gestation and who were treated 
with ECMO for severe respiratory failure could receive hypothermia treatment down to 
34°C for 48 h during ECMO without worsening their cardiovascular status, nor having 
major bleeding. Of note, newborns with severe encephalopathy were excluded from both 
studies. The safety of maintaining hypothermia down to 34°C during ECMO also was 
observed in 37 newborns after cardiac surgery by Lou et al. [33]; none of the newborns 
treated with ECMO and hypothermia developed intracranial hemorrhage or a worsening 
of hemodynamic instability. In addition, Field et al. [22, 34] found that mild hypothermia 
down to 34°C could be safely maintained during ECMO for 72 h with newborns with meco-
nium aspiration, persistent pulmonary hypertension, or severe cardiorespiratory failure. 
When they compared the outcomes at 2 years of age of their 45 newborns treated with 
mild hypothermia to 34°C for 48–72 h during ECMO to the outcomes of their 48 newborns 
treated only with ECMO, the mild hypothermia treatment did not improve the outcomes 
of these 45 newborns [22]. However, given the heterogeneity of the initial diagnoses in this 
studied population of newborns, these results cannot be extrapolated directly to asphyxi-
ated newborns, in whom hypothermia, not in the context of ECMO, has been shown to be 
of benefit [6, 7]. Therefore, as of now, no evidence exists that the incidence of significant 
bleeding and the need for inotropes were worsened when hypothermia was provided to 
newborns during the ECMO course.
4. Feasibility of ECMO with asphyxiated newborns treated with 
hypothermia
The major complications during an ECMO course are hemorrhagic and/or thromboembolic, 
with an increased risk of intracranial hemorrhage. Asphyxiated newborns treated with hypo-
thermia are already at an increased risk of hemodynamic instability, thrombocytopenia, and 
coagulopathy, which are risk factors for intracranial bleeding [35, 36] and further brain injury 
[10, 17] (Figure 1). These complications may be due to the primary asphyxial event or the con-
sequence of the therapeutic hypothermia [8]. Thus, questions have been raised about whether 
providing ECMO treatment for these asphyxiated newborns may worsen their outcome and 
increase their risk of intracranial bleeding.
To date, only a limited number of studies reported on the use of ECMO with asphyxiated 
newborns treated with hypothermia [9–11]. The Cuevas Guaman et al. [10] study is the largest 
of these studies, which included 187 asphyxiated newborns treated with ECMO. They did 
not find any difference in the incidence of bleeding or mortality in the 78 asphyxiated new-
borns treated with hypothermia during the ECMO course, compared to the 109 not-cooled 
asphyxiated newborns treated only with ECMO. These two groups also did not differ in their 
incidence of cardiopulmonary, renal, neurological, and metabolic complications. Therefore, 
according to the currently limited available evidence, it appears that ECMO therapy may be 
run safely with asphyxiated newborns treated with hypothermia.
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5. Short- and long-term outcomes in asphyxiated newborns treated 
with hypothermia and ECMO
Hypothermia treatment has improved the prognosis of asphyxiated newborns, making 
neonatal encephalopathy a “reversible” condition in one of seven treated newborns [37, 38]. 
However, due to their risk of irreversible brain injury, clinicians often are concerned about 
offering ECMO to these newborns [39]. Data on the outcome of asphyxiated newborns who 
received ECMO during the first 72 h of life are scarce [9–11] (Table 1). Shah et al. [11] reported 
on two asphyxiated newborns treated with hypothermia and ECMO who survived, but they 
did not mention their outcome. Massaro et al. [9] reported on five asphyxiated newborns 
treated with hypothermia and ECMO: they all survived and three of them were develop-
mentally age appropriate at follow-up at 6–21 months; one had increased tone at 3 months 
but then was lost to follow up; and one had significant motor and cognitive delay. Cuevas 
Guaman et al. [10] studied 78 asphyxiated newborns treated with hypothermia and ECMO 
and reported a 15% mortality, 22% neurological complications (e.g., brain hemorrhage or 
infarction), and 12% seizure rate; however, they did not report on the long-term outcomes of 
these newborns. Thus, current evidence suggests that the outcome of asphyxiated newborns 
treated with hypothermia and ECMO is not always poor.
In addition, to achieve optimal results, early rather than later consideration of ECMO during 
the course of therapeutic hypothermia is probably important for these critically ill newborns, 
Figure 1. Schematic explaining indications of hypothermia treatment, and potential complications of birth asphyxia and 
hypothermia.
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since a prolonged duration of metabolic acidosis, inotropic support, and a need for inhaled 
nitric oxide prior to ECMO initiation have been associated with a higher rate of bleeding com-
plications [40, 41], and since hemodynamic instability has been associated with worsened brain 
injury in those newborns [16]. In addition, it may be safer to start ECMO, if required, before the 
rewarming phase following the 72-h hypothermia treatment, so to allow hemodynamic sup-
port during this time-period when pulmonary hypertension crises are more likely to occur [11].
6. Considerations for using ECMO in asphyxiated newborns treated 
with hypothermia
ECMO is an expensive and labor-intensive, life-sustaining modality. The ideal candidate for 
ECMO is a patient with a reversible disease condition for whom standard treatments have 
failed to reverse the disease process and for whom mortality risk is high. The most common 
contraindications for neonatal ECMO currently include a gestational age less than 34 weeks, 
weight of less than 2 kg, significant coagulopathy, significant intraventricular hemorrhage, 
and an underlying genetic condition with a poor prognosis [42]. Severe metabolic acidosis 
prior to ECMO also is considered a relative contraindication for ECMO, since this has been 
associated previously with higher mortality and brain injury [43]. However, the successful 
use of ECMO has been reported for a newborn with persistent pulmonary hypertension, pre-
sumed sepsis, and a pre-ECMO pH of less than 6.6 [44]. Thus, asphyxiated newborns treated 
with hypothermia—if they do not present with intraventricular hemorrhage or proven 
severe and irreversible brain injury at the time of cannulation—should be eligible for ECMO. 
Reference Number of newborns Survival rate Outcomes
Shah et al. [11] Two asphyxiated newborns 
treated with hypothermia and 
ECMO
2/2 (100%) 
survived
Long-term neurodevelopmental outcome not 
known
Massaro et al. [9] Five asphyxiated newborns 
treated with hypothermia and 
ECMO
5/5 (100%) 
survived
• 3/5 (60%) developmentally age appropriate at 
follow-up at 6–21 months;
• 1/5 (20%) increased tone at 3 months but then 
was lost to follow up;
• 1/5 (20%) significant motor and cognitive delay
Cuevas Guaman 
et al. [10]
Seventy-eight asphyxiated 
newborns treated with 
hypothermia and ECMO
66/78 (85%) 
survived
Long-term neurodevelopmental outcome not 
known
Short-term outcome included:
• 17/78 (22%) neurological complications (e.g., 
brain hemorrhage or infarction)
• 9/78 (12%) seizure rate
Table 1. Outcomes in asphyxiated newborns treated with hypothermia and extracorporeal membrane oxygenation 
(ECMO).
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If started in an optimal timeframe, ECMO associated with hypothermia treatment may ensure 
adequate oxygenation, treat catecholamines-resistant hypotension, and minimize further 
brain injury in these newborns, without causing intracerebral hemorrhage if coagulopathy 
can be kept under control.
7. Conclusions
In conclusion, ECMO might thus be considered as a therapeutic option for asphyxiated new-
borns treated with hypothermia, if they need it respiratory or hemodynamic support, if they 
have no proven irreversible brain injury visible at the time of starting ECMO.
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